Investigational agents for Crohn's disease
Mario Cottone1, Ambrogio Orlando, Sara Renna
1Department of Internal Medicine, University of Palermo, Ospedale Villa Sofia-Cervello, via trabucco 180, 90146 Palermo, Italy.
Expert Opinion on Investigational Drugs
|September 15, 2010
Summary
New biological therapies for Crohn's disease show promise, with anti-tumor necrosis factor (TNF) and anti-integrin drugs remaining effective. Anti-interleukin-23 (IL-23) therapies are particularly promising, though further research is needed.
Area of Science:
- Gastroenterology and immunology
- Crohn's disease pathogenesis
- Novel therapeutic targets
Background:
- Advances in understanding Crohn's disease biology have led to numerous new drug candidates.
- While some therapies are approved, many are still under clinical evaluation.
Purpose of the Study:
- To review the clinical efficacy of novel biological therapies for Crohn's disease evaluated in controlled trials over the past 12 years.
- To focus on remission rates as the primary endpoint for assessing treatment effectiveness.
Main Methods:
- Brief review of anti-tumor necrosis factor (TNF) therapies.
- In-depth analysis of other biological therapies, including probiotics, cytokines (e.g., IL-10, IL-11), and targeted agents (e.g., anti-IL-6, anti-IL-12/23, anti-integrins).
- Evaluation based on remission rates in controlled clinical trials.
Main Results:
- Analyzed various novel drugs targeting Crohn's disease mechanisms, including probiotics, GM-CSF, IL-10, IL-11, anti-IL-6, anti-IL-12/-23, everolimus, anti-IFN-γ, IFN-β-I, co-stimulators, anti-integrins, anti-ICAM-1, small molecules, and MAPK inhibitors.
- Identified anti-TNF therapies and anti-integrin drugs as current leading treatments.
- Highlighted anti-IL-23 agents as the most promising emerging therapies.
Conclusions:
- Anti-TNF therapies remain the standard of care, with anti-integrin drugs as a strong second option.
- Anti-IL-23 therapies show significant potential, but require additional supporting data.
- Suboptimal trial design or drug dosage may explain disappointing results for other investigated molecules.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...